All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Topical ruxolitinib cream for cutaneous cGvHD: A phase II trial

By Megan Moore

Share:

Nov 19, 2026

Learning objective: After reading this article, learners will be able to cite a new clinical development in cutaneous chronic graft-versus-host disease.


Results from a single-center, randomized, double-blind, intra-patient-controlled, phase II trial (NCT03954236) evaluating topical ruxolitinib 1.5% cream for patients aged ≥12 years with epidermal or superficially sclerotic cutaneous chronic graft-versus-host disease (cGvHD) were published in The Lancet Haematology by Markova et al. Patients were randomly assigned in a 1:1 ratio to receive ruxolitinib 1.5% cream twice daily on either the left or right side of the face and/or body, with placebo vehicle applied to the contralateral lesional skin. The primary endpoint was the absolute between-side difference in affected lesional body surface area (BSA) at Day 28. 

Key data: Among evaluable patients (n = 23), mean affected lesional BSA decreased from 14.3% at baseline to 6.2% at Day 28 on the ruxolitinib-treated side, compared with 14.5% at baseline to 10.4% at Day 28 on the placebo vehicle-treated side (between-side difference, –4.2 percentage points; 95% confidence interval [CI], –6.8 to –1.5; p = 0.0030). After adjustment for baseline differences in BSA between the two sides, the between-side treatment difference was –4.0 percentage points (95% CI, –5.5 to –2.4; p < 0.0010). No treatment-related deaths occurred, and no treatment interruptions or dose modifications due to toxicity were required.

Key learning: In this study, topical ruxolitinib 1.5% cream demonstrated significant clinical activity and a favorable safety profile through Day 28 in patients with epidermal or superficially sclerotic cutaneous cGvHD, supporting its potential as a steroid-sparing, skin-directed alternative or second-line therapy. Further evaluation in larger, prospective trials is warranted. 

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.